Axsome Therapeutics Inc (AXSM) - Net Assets
Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) has net assets worth $54.59 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($713.61 Million) and total liabilities ($659.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Axsome Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $54.59 Million |
| % of Total Assets | 7.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | 464.89% |
| 10-Year Change | 309.31% |
| Growth Volatility | 5677.67 |
Axsome Therapeutics Inc - Net Assets Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Axsome Therapeutics Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual net assets of Axsome Therapeutics Inc from 2013 to 2025. For live valuation and market cap data, see how much is Axsome Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $88.30 Million | +54.86% |
| 2024-12-31 | $57.02 Million | -70.15% |
| 2023-12-31 | $190.98 Million | +74.32% |
| 2022-12-31 | $109.56 Million | +600.92% |
| 2021-12-31 | $15.63 Million | -86.26% |
| 2020-12-31 | $113.79 Million | -36.33% |
| 2019-12-31 | $178.72 Million | +18955.16% |
| 2018-12-31 | $937.92K | -94.39% |
| 2017-12-31 | $16.72 Million | -22.50% |
| 2016-12-31 | $21.57 Million | -53.55% |
| 2015-12-31 | $46.44 Million | +1550.22% |
| 2014-12-31 | $-3.20 Million | -57.93% |
| 2013-12-31 | $-2.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Axsome Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 130373234300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.01% |
| Other Components | $1.39 Billion | 1579.08% |
| Total Equity | $88.30 Million | 100.00% |
Axsome Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Axsome Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AB SKF (publ)
ST:SKF-B
|
$11.20 Billion |
|
Lupin Limited
NSE:LUPIN
|
$11.20 Billion |
|
BUDWEISER BREW.UNSP.ADR/4
F:4BB1
|
$11.20 Billion |
|
Suzhou TA&A Ultra Clean Technology Co Ltd
SHE:300390
|
$11.21 Billion |
|
Dayforce Inc.
NYSE:DAY
|
$11.18 Billion |
|
Eurofins Scientific SE
F:ESF0
|
$11.18 Billion |
|
JAMES HARDIE INDUST.ADR/1
F:JHA0
|
$11.18 Billion |
|
Nordex SE
F:NDX1
|
$11.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Axsome Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 57,015,000 to 88,295,000, a change of 31,280,000 (54.9%).
- Net loss of 183,174,000 reduced equity.
- New share issuances of 67,904,000 increased equity.
- Other factors increased equity by 146,550,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-183.17 Million | -207.46% |
| Share Issuances | $67.90 Million | +76.91% |
| Other Changes | $146.55 Million | +165.98% |
| Total Change | $- | 54.86% |
Book Value vs Market Value Analysis
This analysis compares Axsome Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 131.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.26 | $234.20 | x |
| 2014-12-31 | $-0.25 | $234.20 | x |
| 2015-12-31 | $3.89 | $234.20 | x |
| 2016-12-31 | $1.13 | $234.20 | x |
| 2017-12-31 | $0.73 | $234.20 | x |
| 2018-12-31 | $0.03 | $234.20 | x |
| 2019-12-31 | $5.25 | $234.20 | x |
| 2020-12-31 | $3.06 | $234.20 | x |
| 2021-12-31 | $0.42 | $234.20 | x |
| 2022-12-31 | $2.69 | $234.20 | x |
| 2023-12-31 | $4.20 | $234.20 | x |
| 2024-12-31 | $1.19 | $234.20 | x |
| 2025-12-31 | $1.77 | $234.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Axsome Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -207.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.69%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 7.81x
- Recent ROE (-207.46%) is above the historical average (-432.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.96 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.68 Million |
| 2015 | -26.29% | 0.00% | 0.00x | 1.06x | $-16.86 Million |
| 2016 | -126.10% | 0.00% | 0.00x | 1.77x | $-29.36 Million |
| 2017 | -173.14% | 0.00% | 0.00x | 2.13x | $-30.62 Million |
| 2018 | -3301.50% | 0.00% | 0.00x | 16.40x | $-31.06 Million |
| 2019 | -38.24% | 0.00% | 0.00x | 1.23x | $-86.22 Million |
| 2020 | -90.43% | 0.00% | 0.00x | 1.64x | $-114.28 Million |
| 2021 | -863.34% | -1530.01% | 0.10x | 5.62x | $-136.51 Million |
| 2022 | -170.81% | -373.99% | 0.15x | 3.03x | $-198.09 Million |
| 2023 | -125.27% | -88.41% | 0.46x | 3.08x | $-258.34 Million |
| 2024 | -503.76% | -74.47% | 0.68x | 9.97x | $-292.92 Million |
| 2025 | -207.46% | -28.69% | 0.93x | 7.81x | $-192.00 Million |
Industry Comparison
This section compares Axsome Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Axsome Therapeutics Inc (AXSM) | $54.59 Million | 0.00% | 12.07x | $11.19 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more